Top 5 Long Term Companies To Watch For 2014

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of biopharmaceutical company Amarin (NASDAQ: AMRN  ) sank 10% today, after announcing plans to sell 21.7 million American depositary shares in a public secondary offering.

So what: The new offering represents around 14% of Amarin's outstanding shares -- with underwriters having a 30-day option to purchase an additional 2% -- so Mr. Market is naturally trying to discount the deal's dilutive effects. Of course, the cash-strapped Amarin said it will use the proceeds to continue the commercial launch of its triglyceride drug Vascepa, so the offering might payoff in the long term.�

Now what: Management will keep seeking approval from the U.S. FDA to market Vascepa as a treatment for patients who have high triglyceride levels and also are taking a statin to control their cholesterol. And as Foolish biotech expert Keith Speights wrote earlier, "There ... appears to be a reasonable chance that the FDA will approve the drug for individuals with high (as opposed to very high) triglyceride levels later this year. Amarin's shares could very well be much higher by year end." So while Amarin remains just too speculative for average Fools, today's double-digit drop -- the stock is now off a whopping 65% from its 52-week highs -- might be an attractive opportunity for biotech-savvy bargain hunters.

10 Best European Stocks To Watch Right Now: Marathon Investments Ltd (MARA)

Marathon Investments Ltd is an Israel-based company that invests in income-producing industrial companies. The Company's portfolio includes companies in the fields of heat treatment, biotechnology, inspection and advanced electronics. Its portfolio comprises of a number of companies: Protalix Biotherapeutics Inc. which produces plant protein-based medical treatment; Nanomotion Ltd. which develops, manufactures and markets tiny solid-state ceramic servo motors and positioning systems; Margan Business Development Ltd. which engages in early building and facility damage detection; BioView Ltd. which develops and manufactures medical screening and diagnostics systems; Solcon Industries Ltd. is a high technology electronics manufacturer, whose products are intended for installation in low and medium voltage AC Motor switchgear, and Chromat Ltd., which is a commercial steel heat treatment company, among others. Advisors' Opinion:

• [By John Udovich]

  Although some view patent investors or speculators as nothing more than "patent trolls," small cap patent stocks RPX Corporation (NASDAQ: RPXC), Marathon Patent Group Inc (OTCBB: MARA) and Endeavor IP Inc (OTCBB: ENIP) are a couple of interesting options that allow retail investors to invest in patents as they either invest in patents themselves or they provide patent related services. However, there could be risks associated with investing in patent stocks because a bi-partisan bill called the Innovation Act (H.R. 3309) is�working its way through Congress to try and reign in the activities of so-called�patent trolls or companies�who go out and buy or license patents from others and then target alleged infringers with lawsuits.

• [By CRWE]

  Today, MARA has shed (-3.78%) down -0.23 at $5.85 with�23,913 shares in play thus far (ref. google finance Delayed: 11:09AM EDT September 11, 2013).

  Marathon Patent Group, Inc. previously reported its financial results for the second quarter ended June 30, 2013 (“Q2 2013″).
  For Q2, 2013, the Company reported gross revenue of $1,524,979, as a result of three patent licensing and settlement agreements. Q2 2013 marks the first quarter the Company has reported significant licensing and settlement revenue. Included in the gross revenue amount is the value of certain patents received in settlement from a defendant.

Top 5 Long Term Companies To Watch For 2014: Physicians Realty Trust (DOC)

Physicians Realty Trust, incorporated on April 9, 2013, is a real estate investment trust (REIT). The Company is a self-managed healthcare real estate company. The Company is engaged in acquiring, developing, owning and managing healthcare properties that are leased to physicians, hospitals and healthcare delivery systems. The Company invests in real estate that is integral to providing healthcare services. The Company�� properties are located on a campus with a hospital or other healthcare facilities or strategically located and affiliated with a hospital or other healthcare facilities. The Company�� principal investments will include medical office buildings, outpatient treatment facilities, acute and post-acute care hospitals, as well as other real estate integral to healthcare providers. The Company�� initial portfolio will consist of 19 medical office buildings located in 10 states with approximately 528,048 net leasable square feet. Effective August 27, 2013, Physicians Realty Trust acquired an undisclosed hospital, located in Plano, Texas, an owner and operator of hospital. In September 2013, Physicians Realty Trust completion of the sale-leaseback of the surgical hospital and adjacent medical office building occupied by the Foundation Surgical Hospital of El Paso, L.L.C. In October 2013, Physicians Realty Trust announced the completion of the acquisition of the Foundation Outpatient Care Building located in Oklahoma City, OK. Effective January 8, 2014, Physicians Realty Trust acquired an undisclosed ambulatory surgery center, located in Great Falls, Montana. In February 2014, the Company's operating partnership, Physicians Realty L.P., closed on the purchase and leaseback of four medical office buildings to an Atlanta, Georgia-based family medical practice.

The Company�� Surgical Hospital-New Orleans, Louisiana property is a 57,000 square foot, 42-bed acute care surgical hospital with six operating rooms. The hospital specializes in ortho/neuro spine surgery, orthopedics, ! weight loss surgery and other scheduled general surgery procedures. Surgical Hospital and Medical Office Building-El Paso, Texas property is a 77,000 square foot, 40-bed acute care hospital with six operating rooms. The Company's initial portfolio was acquired or developed by healthcare real estate funds managed by B.C. Ziegler & Company (Ziegler), a specialty investment banking firm focused on the healthcare industry, and another subsidiary of The Ziegler Companies, Inc. As part of its formation transactions, the Ziegler Funds will contribute their ownership interests in these properties to its operating partnership.

Advisors' Opinion:

• [By Marc Bastow]

  Healthcare REIT Physicians Realty Trust (DOC) was right up their with Ford in raising its quarterly dividend 25%, to 22.5 cents per share, payable Feb. 7 to shareholders of record as of Jan. 24.
  DOC Stock Dividend Yield: 7.02%

Top 5 Long Term Companies To Watch For 2014: VIVUS Inc (VVUS)

VIVUS, Inc., incorporated on May 16, 1996, is a biopharmaceutical company. It commercializes and develops therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health. The Company's drug, Qsymia (phentermine and topiramate extended-release) was approved by the the United States Food and Drug Administration (FDA) for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 or greater (obese), or 27 or greater (overweight) in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol (dyslipidemia). Qsymia incorporates low doses of active ingredients from two previously approved drugs, phentermine and topiramate. It has completed Phase 2 clinical studies for Qsymia for the treatment of sleeps apnea and Qsymia for the treatment of type 2 diabetes. Its drug also includes STENDRA, or avanafil.

Qsymia for the treatment of obesity was approved as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial BMI of 30 or greater (obese), or 27 or greater (overweight) in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol (dyslipidemia). Qsymia incorporates low doses of active ingredients from two previously approved drugs, phentermine and topiramate.

The Company initially launched Qsymia for distribution to eligible patients through the home delivery networks of two certified pharmacies, CVS Pharmacy and Walgreens. Since then, it has expanded the distribution of Qsymia to include the home delivery networks of Express Scripts, Wal-Mart Pharmacy and, for its members only, Kaiser Permanente. Clinical studies of topiramate, a component of Qsymia, in type 2 diabetics resulted in a clinically reduction of hemoglobin A1c (HbA1c). The! Company's drug, STENDRA (avanafil), is an oral PDE5 inhibitor the Company has licensed from Mitsubishi Tanabe Pharma Corporation (MTPC).

Advisors' Opinion:

• [By Brian Orelli]

  On Saturday, VIVUS (NASDAQ: VVUS  ) extended an olive branch to its largest shareholder and proxy-fight-adversary First Manhattan, offering to give the hedge fund three board seats whether First Manhattan won seats or not.

• [By Maria Armental var popups = dojo.query(".socialByline .popC"); popups.forEach]

  Vivus Inc.(VVUS) said it filed a patent-infringement lawsuit against Actavis (ACT) PLC alleging that the drug maker’s planned generic version of weight-loss drug Qsymia infringes its patents.

Top 5 Long Term Companies To Watch For 2014: Senomyx Inc.(SNMX)

Senomyx, Inc. engages in the discovery and development of novel flavor ingredients in the savory, sweet, salt, bitter, and cooling areas using proprietary taste receptor-based assays and screening technologies. The company has product discovery, development, and commercialization collaborations with seven food, beverage, and ingredient companies, including Ajinomoto Co., Inc.; Firmenich SA; Kraft Foods, Inc.; Nestle SA; and PepsiCo, Inc. Senomyx, Inc. licenses flavor ingredients to its collaborators on an exclusive or co-exclusive basis. The company was founded in 1998 and is based in San Diego, California.

Advisors' Opinion:

• [By Jake L'Ecuyer]

  Leading and Lagging Sectors
  Healthcare stocks gained Wednesday, with Senomyx (NASDAQ: SNMX) leading advancers after the company announced a research agreement with PepsiCo (NYSE: PEP). Among the leading sector stocks, gains came from Pernix Therapeutics Holdings (NASDAQ: PTX), Albany Molecular Research (NASDAQ: AMRI) and Gentiva Health Services (NASDAQ: GTIV).